Clinical nuclear medicine
-
Clinical nuclear medicine · May 2013
Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
This study aimed to investigate the correlation of 18F-FDG PET/CT findings with histopathological results in defining the recurrence of the disease in patients with differentiated thyroid cancer (DTC) who have increased thyroglobuline (Tg) or anti-Tg antibody (TgAb) levels and negative 131I whole-body scan (WBS) result. ⋯ 18F-FDG PET/CT may be a useful imaging modality in defining recurrence of the disease in patients with DTC who have increased Tg or TgAb levels, negative 131I-WBS results, and negative or suspicious neck ultrasonography and/or thorax CT results. Although 18F-FDG PET/CT seems to be a more sensitive method in patients with increased TgAb levels, the number of patients is not enough to make a substantiated comment.
-
Clinical nuclear medicine · Apr 2013
Can (18)F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer?
Where chemoradiotherapy or radiotherapy alone with curative intent is used as the primary treatment of locally advanced head and neck cancers, salvage surgery may offer a second chance of cure in the face of recurrent or residual disease. Early detection of recurrent or residual disease is therefore the key to facilitating timely and efficacious salvage surgery. CT and MRI can be difficult to interpret in the posttreatment neck. Functional imaging, such as F-FDG PET/CT, has the potential to improve restaging accuracy. The aim of our study was to assess the efficacy of F-FDG PET/CT performed 3 months following primary treatment of head and neck cancer. ⋯ F-FDG PET/CT is an accurate method for assessing response after primary locally advanced head and neck cancer treatment. Although false-positive scans are rare, a few patients will have a relapse after a negative scan, and so continued close follow-up is required.
-
Clinical nuclear medicine · Mar 2013
The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
The aim of this study was to assess the value of dual-time point PET/CT in the differentiation of extrahepatic cholangiocarcinoma from benign stricture and the added benefits of delayed PET/CT image. ⋯ SUVmax from both early and delayed PET/CT scans are useful parameters in the differentiation of extrahepatic biliary malignancy from benign disease. However, there was no added benefit of delayed PET/CT in patients suspicious for extrahepatic cholangiocarcinoma.
-
Clinical nuclear medicine · Feb 2013
MRI and FDG PET/CT findings of hepatic epithelioid hemangioendothelioma.
The aim of this study was to evaluate retrospectively magnetic resonance imaging (MRI) and (18)F fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) findings of hepatic epithelioid hemangioendothelioma (HEH). ⋯ MRI demonstrated morphological features of HEH and FDG PET/CT reflected the histopathological composition of the tumors. FDG uptake of HEH may be related to tumor cellularity, but not the tumor size. Dual-time-point imaging may be not useful for differentiating benign lesions from HEH. Familiarity with the morphological and functional imaging findings of HEH is useful for recognition of this rare hepatic tumor.
-
Clinical nuclear medicine · Feb 2013
Case ReportsHepatoblastoma evaluated by 18F-fluoromethyl choline PET/CT.
Hepatoblastoma is a rare carcinoma mostly seen in children. Neoadjuvant chemotherapy followed by resection and adjuvant chemotherapy is the optimal treatment. ⋯ Laboratory examinations revealed plasma α-feto-protein of 114,245 μg/L. Subsequent baseline and posttreatment F-fluoromethyl choline PET/CT were performed to possibly evaluate extent of the disease and assess disease response after neoadjuvant chemotherapy.